Literature DB >> 18435426

The impact of using different imputation methods for missing quality of life scores on the estimation of the cost-effectiveness of lung-volume-reduction surgery.

David K Blough1, Scott Ramsey, Sean D Sullivan, Roger Yusen.   

Abstract

A post hoc analysis of data from a prospective cost-effectiveness analysis (CEA) conducted alongside a randomized controlled trial (National Emphysema Treatment Trial - NETT) was used to assess the impact of using different imputation methods for missing quality of life data on the estimation of the incremental cost-effectiveness ratio (ICER). The NETT compared lung-volume-reduction surgery plus medical therapy with medical therapy alone in patients with severe chronic obstructive pulmonary disease due to emphysema. One thousand sixty-six patients were followed for up to 3 years after randomization. The cost per quality-adjusted life-year gained was obtained, computing costs from a societal perspective and using the self-administered Quality of Well Being questionnaire to measure quality of life. Different methods of imputation resulted in substantial differences in ICERs as well as differences in estimates of the uncertainty in the point estimates as reflected in the CEA acceptability curves. Paradoxically, the use of a conservative single imputation method resulted in relatively less uncertainty (anticonservative) about the ICER. Owing to the effects of different imputation methods for missing quality of life data on the estimation of the ICER, we recommend use of a minimum of two imputation methods that always include multiple imputation. Copyright (c) 2008 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2009        PMID: 18435426     DOI: 10.1002/hec.1347

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  8 in total

1.  Estimation of a physician practice cost function.

Authors:  Lukas Kwietniewski; Mareike Heimeshoff; Jonas Schreyögg
Journal:  Eur J Health Econ       Date:  2016-05-19

Review 2.  Quality of life in lung transplantation.

Authors:  Jonathan P Singer; Lianne G Singer
Journal:  Semin Respir Crit Care Med       Date:  2013-07-02       Impact factor: 3.119

3.  Handling missing data in a composite outcome with partially observed components: simulation study based on clustered paediatric routine data.

Authors:  Susan Gachau; Edmund Njeru Njagi; Nelson Owuor; Paul Mwaniki; Matteo Quartagno; Rachel Sarguta; Mike English; Philip Ayieko
Journal:  J Appl Stat       Date:  2021-03-17       Impact factor: 1.416

4.  Multiple imputation to deal with missing EQ-5D-3L data: Should we impute individual domains or the actual index?

Authors:  Claire L Simons; Oliver Rivero-Arias; Ly-Mee Yu; Judit Simon
Journal:  Qual Life Res       Date:  2014-12-04       Impact factor: 4.147

5.  Cost-Effectiveness and Return-on-Investment of a Participatory Ergonomics Intervention Among Childcare Workers: An Economic Evaluation in a Randomized Controlled Trial.

Authors:  Nidhi Gupta; Johanna M van Dongen; Andreas Holtermann; Allard J van der Beek; Matthew Leigh Stevens; Charlotte Diana Nørregaard Rasmussen
Journal:  J Occup Environ Med       Date:  2022-02-09       Impact factor: 2.306

6.  A guide to handling missing data in cost-effectiveness analysis conducted within randomised controlled trials.

Authors:  Rita Faria; Manuel Gomes; David Epstein; Ian R White
Journal:  Pharmacoeconomics       Date:  2014-12       Impact factor: 4.981

7.  Is the whole larger than the sum of its parts? Impact of missing data imputation in economic evaluation conducted alongside randomized controlled trials.

Authors:  Bernhard Michalowsky; Wolfgang Hoffmann; Kevin Kennedy; Feng Xie
Journal:  Eur J Health Econ       Date:  2020-02-27

8.  Multiple imputation for patient reported outcome measures in randomised controlled trials: advantages and disadvantages of imputing at the item, subscale or composite score level.

Authors:  Ines Rombach; Alastair M Gray; Crispin Jenkinson; David W Murray; Oliver Rivero-Arias
Journal:  BMC Med Res Methodol       Date:  2018-08-28       Impact factor: 4.615

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.